An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a company focused on innovative therapies for glaucoma and retinal diseases, announced that Interim Executive Chairman Benjamin McGraw, III, Pharm.D. will participate in three upcoming virtual investor conferences. These include the Stifel 2021 Virtual Healthcare Conference on November 16, Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, and Ophthalmology Day at BTIG on November 30. Live presentations and replays will be accessible on Aerie’s website.
Positive
None.
Negative
None.
DURHAM, N.C.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.
Select presentations will be available live and for replay viewing by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of certain webcasts will be available for 90 days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye, wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.
Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc. Hans Vitzthum hans@lifesciadvisors.com
(617) 430-7578
Source: Aerie Pharmaceuticals, Inc.
FAQ
When will Aerie Pharmaceuticals participate in the Stifel 2021 Virtual Healthcare Conference?
Aerie Pharmaceuticals will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 a.m. Eastern Time.
What time is the Piper Sandler 33rd Annual Virtual Healthcare Conference for Aerie Pharmaceuticals?
The Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on November 22, 2021, starting at 10:00 a.m. Eastern Time.
What is the date for the Ophthalmology Day at BTIG that Aerie Pharmaceuticals will attend?
Ophthalmology Day at BTIG is scheduled for November 30, 2021, at 11:00 a.m. Eastern Time.
Where can I watch the presentations from Aerie Pharmaceuticals' upcoming conferences?
Select presentations from Aerie Pharmaceuticals' upcoming conferences will be available live and for replay on their website at http://investors.aeriepharma.com.
What is Aerie Pharmaceuticals known for?
Aerie Pharmaceuticals specializes in developing therapies for open-angle glaucoma, ocular surface diseases, and retinal diseases.
